An approach to managing depression. Defining and measuring outcomes

Canadian Family Physician

Volumn 50, Issue OCT., 2004, Pages 1374-1380

  Khullar, Atul ^a   McIntyre, Roger S ^b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ANHEDONIA; ANXIETY DISORDER; ARTICLE; BEHAVIOR THERAPY; BIPOLAR DISORDER; CANADA; CHRONIC DISEASE; COGNITIVE THERAPY; DISEASE COURSE; EXPERIENCE; GENERAL PRACTITIONER; HAMILTON SCALE; HEALTH CARE ORGANIZATION; HUMAN; LIFESTYLE; LONG TERM CARE; MAJOR DEPRESSION; MEDLINE; MONITORING; NONBIOLOGICAL MODEL; OUTCOMES RESEARCH; PHYSICIAN; PRACTICE GUIDELINE; PSYCHIATRY; PSYCHODYNAMICS; PSYCHOSOMATIC DISORDER; PSYCHOTHERAPY; RATING SCALE; RECURRENT DISEASE; RELAPSE; REMISSION; SYMPTOMATOLOGY; TREATMENT PLANNING;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DIFFERENTIAL; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY;

EID: 6444233838     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
2. Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, Mass: Harvard University Press; 1996.
3. Von Korff M, Ormel J, Katon W, Lin EH. Disability and depression among high utilizers of health care: a longitudinal analysis. Arch Gen Psychiatry 1992;49(2):91-100.
4. Judd LL, Akiskal HS, Zeller PJ, Paulus M, Leon AC, Maser JD, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 2000;57(4):375-80.
5. Tylee A. Depression in the community: physician and patient perspective. J Clin Psychiatry 1999;60(Suppl 7):12-6. Discussion 1999;60(Suppl 7):17-8.
6. Parikh SV, Lam RW. Clinical guidelines for the treatment of depressive disorders. I. Definitions, prevalence, and health burden. Can J Psychiatry 2001;46(Suppl 1):13-20S.
7. Reesal RT, Lam RW. Clinical guidelines for the treatment of depressive disorders. II. Principles of management. Can J Psychiatry 2001;46(Suppl 1):21-28S.
8. Segal ZV, Whitney DK, Lam RW. Clinical guidelines for the treatment of depressive disorders. III. Psychotherapy. Can J Psychiatry 2001;46(Suppl 1):29-37S.
9. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46(Suppl 1):38-58S.
10. Segal ZV, Kennedy SH, Cohen NL. Clinical guidelines for the treatment of depressive disorders. V. Combining psychotherapy and pharmacotherapy. Can J Psychiatry 2001;46(Suppl 1):59-62S.
11. Thorpe L, Whitney DK, Kutcher SP, Kennedy SH. Clinical guidelines for the treatment of depressive disorders. VI. Special populations. Can J Psychiatry 2001;46(Suppl 1):63-76S.
12. Enns MW, Swenson JR, McIntyre RS, Swinson RP, Kennedy SH. Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity. Can J Psychiatry 2001;46(Suppl 1):77-90S.
13. Manning JS, Haykal RF, Connor PD, Akiskal HS. On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry 1997;38(2):102-8.
14. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994;31(4):281-94.
15. Manning JS, Haykal RF, Akiskal HS. The role of bipolarity in depression in the family practice setting. Psychiatr Clin North Am 1999;22(3):689-703.
16. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE Jr, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000;157(11):1873-5.
17. Piver A, Yatham LN, Lam RW. Bipolar spectrum disorders. New perspectives. Can Fam Physician 2002;48:896-904.
18. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 Suppl):1-50.
19. Hamilton M. Development of a rating scale for depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
20. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):5-9.
21. McIntyre R, Kennedy S, Bagby RM, Bakish D. Assessing full remission. J Psychiatry Neurosci 2002;27(4):235-9.
22. Bech P. The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure. Acta Psychiatr Scand 2002;106(4):252-64.
23. Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res 1993;27(3):259-73.
24. Maier W, Philipp M. Comparative analysis of observer depression scales. Acta Psychiatr Scand 1985;72(3):239-45.
25. O'Sullivan RL, Fava M, Agustin C, Baer L, Rosenbaum JF. Sensitivity of the six-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 1997;95(5):379-84.
26. Hooper CL, Bakish D. An examination of the sensitivity of the six-item Hamilton Rating Scale for Depression in a sample of patients suffering from major depressive disorder. J Psychiatry Neurosci 2000;25(2):178-84.
27. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 2000;34(1):3-10.
28. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 1974;7(0):151-69.
29. Thase ME. Methodology to measure onset of action. J Clin Psychiatry 2001;62(Suppl 15):18-21.
30. Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 1997;54(11):989-91.
31. Kennedy S. Full remission: a return to normal functioning. J Psychiatry Neurosci 2002;27(4):233-4.
32. Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002;27(4):269-80.
33. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157(9):1501-4.
34. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-99.
35. Ormel J, Oldehinkel T, Brilman E, Vanden Brink W. Outcome of depression and anxiety in primary care. A three-wave 3 1/2-year study of psychopathology and disability. Arch Gen Psychiatry 1993;50(10):759-66.
36. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):26-31.
37. Nierenberg AA, McColl RD. Management options for refractory depression. Am J Med 1996;101(6A):45S-52S.
38. O'Leary D, Costello F, Gormley N, Webb M. Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients. J Affect Disord 2000;57(1-3):159-71.
39. Tranter R, O'Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002;27(4):241-7.
40. Camacho P, Pitale S, Abraira C. Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus. Drugs Aging 2000;17(6):463-76.
41. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998;280(17):1490-6.
42. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ 1998;159(Suppl 8):S1-29.
43. Burns DD. Feeling good handbook. 2nd ed. London, Engl: Plume Publishing; 1999.
44. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):10-17.
45. McIntyre R, Muller A, Mancini D, Silver E. What to do if the initial antidepressant fails? Can Fam Physician 2003;49:449-57.
46. Segal Z, Vincent P, Levitt A. Efficacy of combined, sequential and crossover psychotherapy and pharmacotherapy in improving outcomes in depression. J Psychiatry Neurosci 2002;27(4):281-90.
47. Hirschfeld R, Montgomery S, Aguglia E, Amore M, Delgado P, Gastpar M, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002;63(9):826-37.
48. Lam RW, Wan DD, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry 2002;63(9):685-93.
49. Linden M, Lecrubier Y, Bellantuono C, Benkert O, Kisely S, Simon G. The prescribing of psychotropic drugs by primary care physicians: an international collaborative study. J Clin Psychopharmacol 1999;19(2):132-40.
50. Singh NA, Clements KM, Singh MA. The efficacy of exercise as a long-term antidepressant in elderly subjects: a randomized, controlled trial. J Gerontol A Biol Sci Med Sci 2001;56(8): M497-504.